Generic Name: selpercatinib
Drug Class: Targeted Therapy Medications
Company: Eli Lilly and Company
Approval Status: Approved
Generic Version Available: No
Experimental Code: LOXO-292
Retevmo is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer and advanced or metastatic thyroid cancer with RET gene fusions or mutations.
Retevmo blocks the RET protein, which plays a role in cell proliferation. Mutations or fusions in the RET gene can lead to greater activity that drives the development of cancer. These RET alterations are rare overall, occurring in less that 1% of all cancers, but they are present in a majority of medullary thyroid tumors.
The LIBRETTO-001 trial showed that Retevmo led to complete or partial tumor shrinkage in 64% of previously treated adults with RET fusion-positive non-small-cell lung cancer, rising to 85% for those starting treatment for the first time. The overall response rate was 69% for treatment-experienced and 73% for previously untreated adults and adolescents with RET-mutant medullary thyroid tumors, and 79% and 100%, respectively, for those with RET fusion-positive thyroid cancer. Retevmo was first approved in May 2020.
Retevmo is taken as a capsule twice daily.
Common adverse reactions included diarrhea, constipation, dry mouth, fatigue, swelling, rash, high blood pressure, elevated ALT and AST liver enzymes, elevated glucose and cholesterol, and other lab test abnormalities. Potential serious side effects may include liver toxicity, severe high blood pressure, bleeding, heart rhythm abnormalities, hypersensitivity reactions and slow wound healing. Retevmo can cause fetal harm if used during pregnancy.
For More Info: http://pi.lilly.com/us/retevmo-uspi.pdf
Patient Assistance Program Info: https://www.retevmo.com/savings-support
Last Reviewed: May 10, 2020